• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6848.TWO
Share

RBC Bioscience Corporation Stocks

NT$ 19.25Last Updated 30.07.2026

Issuer Rating

4/7
Performance

Strong

Risk

High

Recommendation

Hold

Market Cap

NT$ 8.88M

NT$ 19.25
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

RBC Bioscience Corporation is a firm dedicated to the research, development, production, and sale of specialized reagents and advanced equipment. These products cater to the life sciences and molecular diagnostic sectors. Its market reach is extensive, covering Europe, the United States, Asia, Taiwan, Africa, and Australia. The company's diverse product line includes reagents tailored for molecular biomedical diagnostics and scientific research, alongside automated instruments for gene and nucleic acid extraction. It also provides a range of nucleic acid extraction kits and associated reagent tissues. Sales are primarily conducted through a global network of distributors. Established in 1995, RBC Bioscience Corporation maintains its headquarters in New Taipei City, Taiwan.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 21:41

Amazon's AI spending has spiraled out of control, and the company is now trying to rein it in — FT

30.07.2026 21:41

Adidas shares plummeted at a record pace. What does the World Cup have to do with this?

30.07.2026 21:00

"Protection Against AI on Wall Street": What the Market Expects from Apple's Report

30.07.2026 20:09

Meta Lost $100 Billion in Market Value Amid Zuckerberg's Attempts to Sell an AI Concept

30.07.2026 19:30

"Volatility Is the New Normal": Shell Posts Second-Highest Profit in Its History

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026